Ginkgo Bioworks Holdings (DNA) Earnings Date & Reports

Key Takeaways

• Ginkgo Bioworks (NYSE: DNA) reported third quarter 2026 revenue of $27.7 million, slightly below the $29.4 million recorded in the same period a year earlier.
• Loss per share from continuing operations narrowed to $0.64, compared with $1.32 in the prior-year quarter, coming in ahead of consensus expectations.
• Revenue of roughly $28 million topped the consensus estimate of about $21.6 million, according to Investing.com data.
• Ginkgo announced its first autonomous lab sale to a top-tier pharmaceutical company, Novo Nordisk, a milestone in its pivot toward automated research infrastructure.
• Cash, cash equivalents, and marketable securities totaled approximately $285 million as of September 30, 2026, down from $423 million at the end of 2025.
• The company continues to operate as a single reporting segment after completing the divestiture of its Biosecurity business earlier in 2026.
• For more context on this ticker, you can explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• You can also discover additional market ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Ginkgo Bioworks is in the middle of a strategic transformation, shifting away from its legacy cell-engineering and biosecurity businesses toward autonomous laboratories that use robotics to replace manual lab work. This quarter's report matters because it offers the clearest signal yet on whether that pivot is generating commercial traction. After divesting its Biosecurity segment in April 2026, Ginkgo now reports as a single segment, making revenue trends, cash burn, and early autonomous lab adoption the central metrics for investors. The first autonomous lab sale to a major pharmaceutical customer suggests the strategy is moving from concept to contract, while narrowing losses indicate the restructuring is beginning to pay off.

Reported Results

For the third quarter ended September 30, 2026, Ginkgo Bioworks reported revenue of $27.7 million, down from $29.4 million in the prior-year period. The loss from continuing operations narrowed to $41.0 million from $73.4 million a year earlier, reflecting the benefits of ongoing restructuring efforts. Loss per share from continuing operations came in at $0.64, compared with $1.32 in the third quarter of 2025.

The results landed ahead of Wall Street expectations. Investing.com data indicated that the company reported a third quarter loss of $0.64 per share, beating the consensus estimate of a $1.01 loss by $0.37, while revenue of roughly $28 million topped the consensus forecast of about $21.6 million. The narrower-than-expected loss and stronger revenue both stemmed from disciplined cost control and improving momentum in Ginkgo's autonomous lab offerings.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for anyone looking to complement fundamental research with data-driven signals.

Market Reaction and Investor Sentiment

Investor sentiment around Ginkgo Bioworks has been improving ahead of this report, with the stock up roughly 25% over the prior three months even as it remained down about 12% over the trailing year. The announcement of the company's first autonomous lab sale to Novo Nordisk, combined with an earnings beat and revenue that exceeded consensus, provided a positive catalyst that reinforced the narrative around Ginkgo's strategic repositioning. Investors have increasingly been evaluating the company on the pace of autonomous lab adoption and its ability to control cash burn rather than on top-line growth alone, and this quarter's results offered early evidence of progress on both fronts.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether the first Novo Nordisk autonomous lab sale translates into a repeatable commercial model. The company has signaled ambitions to double the size of Nebula, its flagship autonomous lab, during 2026, and the pace of that expansion will be a key indicator of both demand and execution risk.

Cash burn remains a central concern. Ginkgo had previously reaffirmed a full-year 2026 cash burn target of $125 million to $150 million, and the company's declining cash balance underscores the importance of hitting that range. Continued progress on subleasing excess lab space and reducing fixed costs will be critical to extending the company's financial runway.

Finally, monitor adoption of the Cloud Lab, Datapoints, and Solutions offerings, which are designed to generate revenue today while strengthening the underlying platform. If autonomous lab demand broadens beyond a single marquee customer, it could mark an inflection point for the business; if adoption stalls, the company's reliance on its remaining cash reserves would come into sharper focus.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations